The Phase II study of sonrotoclax combined with zanubrutinib in patients with relapsed/refractory mantle cell lymphoma (MCL) represents a strategic approach to enhance CAR-T cell therapy outcomes. The dual mechanism targeting BCL-2 and BTK is anticipated to provide synergistic effects, potentially leading to improved response rates and durability of treatment. Given the increasing prevalence of MCL and the limitations of current therapies, this combination could capture significant market share, particularly in the context of unmet medical needs in relapsed/refractory cases. The involvement of the Canadian Cancer Trials Group and BeOne Medicines indicates a robust collaborative effort, which may enhance the credibility and visibility of the trial. However, the competitive landscape includes existing therapies such as ibrutinib and venetoclax, necessitating careful positioning and differentiation of this combination therapy.